DUBLIN--(BUSINESS WIRE)--The "CRISPR/Cas in Therapeutics & Cellular studies" report has been added to ResearchAndMarkets.com's offering.
Over the last few decades, Gene editing took a new turn with the discovery of CRISPR and its variant Cas9. CRISPR not only gave a new image to gene editing but also raised the standards for new findings. CRISPR has been widely used for study or treatment of various diseases viz. Cancer, Huntington's disease, infectious diseases etc. CRISPR together with stem cell are widely been employed for creation of disease models, multiple tissue engineering tasks.
The influencing factor for the escalated growth of CRISPR-Cas system are progressive gene therapy, disease prevalence, grants/funding etc. The present report studies application of CRISPR in therapeutics & Cellular studies in past 20 years.
The key players (Maximum filing) in CRISPR-Cas system based therapeutics/ cellular studies are: Broad institute, MIT, Harvard college, University California, Regeneron pharma etc.
Key Topics Covered:
1. Executive Summary
2. Technology Overview
3. CRISPR/Cas in Therapeutics & Cellular studies
4. Trends & Future Perspectives
Companies Mentioned
- Broad institute
- MIT
- Harvard college
- University California
- Regeneron pharma
For more information about this report visit https://www.researchandmarkets.com/research/kmlmtv/crisprcas_in?w=4
